Amphastar Pharmaceuticals (AMPH) Rises As Market Takes a Dip: Key Facts
In the latest trading session, Amphastar Pharmaceuticals (AMPH) closed at $44.72, marking a +0.52% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.17%. Meanwhile, the Dow experienced a drop of 0.58%, and the technology-dominated Nasdaq saw an increase of 0.27%.
Shares of the specialty pharmaceutical company have depreciated by 2.24% over the course of the past month, outperforming the Medical sector's loss of 5.22% and the S&P 500's loss of 3.95%.
Investors will be eagerly watching for the performance of Amphastar Pharmaceuticals in its upcoming earnings disclosure. On that day, Amphastar Pharmaceuticals is projected to report earnings of $0.70 per share, which would represent year-over-year growth of 84.21%. Simultaneously, our latest consensus estimate expects the revenue to be $170.65 million, showing a 42.05% escalation compared to the year-ago quarter.
AMPH's full-year Zacks Consensus Estimates are calling for earnings of $2.72 per share and revenue of $642.66 million. These results would represent year-over-year changes of +38.07% and +28.79%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Amphastar Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Right now, Amphastar Pharmaceuticals possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Amphastar Pharmaceuticals has a Forward P/E ratio of 16.34 right now. Its industry sports an average Forward P/E of 14, so one might conclude that Amphastar Pharmaceuticals is trading at a premium comparatively.
The Medical - Generic Drugs industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 91, placing it within the top 37% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report
